Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 21.0%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 4,044,938 shares, an increase of 21.0% from the February 26th total of 3,341,948 shares. Based on an average daily trading volume, of 1,121,408 shares, the short-interest ratio is presently 3.6 days. Approximately 19.0% of the shares of the stock are short sold.

Citius Pharmaceuticals Stock Down 6.3%

Shares of NASDAQ CTXR opened at $0.84 on Thursday. The firm has a 50-day simple moving average of $0.79 and a 200-day simple moving average of $1.04. The stock has a market capitalization of $18.87 million, a price-to-earnings ratio of -0.34 and a beta of 1.51. Citius Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $2.48.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings results on Friday, February 13th. The company reported ($0.38) earnings per share for the quarter. As a group, equities research analysts expect that Citius Pharmaceuticals will post -4.5 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CTXR. XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at approximately $32,000. NewEdge Advisors LLC purchased a new position in Citius Pharmaceuticals during the second quarter worth approximately $40,000. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals during the fourth quarter worth $46,000. Finally, Heights Capital Management Inc. acquired a new position in Citius Pharmaceuticals during the fourth quarter worth $622,000. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Citius Pharmaceuticals in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. Finally, Wall Street Zen upgraded Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.